WALTHAM, MA – Syndax Pharmaceuticals Inc. (NASDAQ:SNDX), a biopharmaceutical company focused on the development of cancer therapies, disclosed in a recent SEC filing that the company has eliminated the role of Chief Medical (TASE:PMCN) Officer (CMO). Dr. Catherine Madigan, who served as the CMO, will depart from her position effective today.
The company stated that this organizational change is in line with the terms outlined in Dr. Madigan's service agreement. Specific details regarding the severance compensation for Dr. Madigan were referenced in the company's Annual Report on Form 10-K for the fiscal year ending December 31, 2023.
Syndax Pharmaceuticals, incorporated in Delaware and based in Waltham, Massachusetts, is recognized under the Standard Industrial Classification (SIC) code 2834, which pertains to pharmaceutical preparations.
The announcement comes without further elaboration on the reasons behind the elimination of the CMO position or the company's future strategic direction in the wake of this change. The information is based on a press release statement.
Syndax's business address remains at 35 Gatehouse Drive, Building D, Floor 3, Waltham, MA 02451, and the company can be reached at the phone number (781) 419-1400.
The filing was made in accordance with the requirements of the Securities Exchange Act of 1934 and was signed by Michael A. Metzger, Chief Executive Officer of Syndax Pharmaceuticals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.